News & insights

Prime Therapeutics is pivoting to a new rebate model and fighting back against accusations of collusion

Prime Therapeutics, one of the largest US pharmacy benefit managers, aims to shift to upfront drug pricing and away from a complicated rebates-based system that critics say increases patient costs.

Mostafa Kamal, CEO of Prime, told Fierce Healthcare in an interview that patients don't necessarily experience a complex condition through the lens of separate medical and pharmacy benefits, so their care experience should reflect that.

Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.

Mostafa Kamal, chief executive officer at Prime Therapeutics, shares why the key question in the drug pricing debate is not just where health care value is created, but whether it ultimately reaches the patients, employers and health plans paying for care.

Zach Jones, Pharm.D., is senior director of clinical formulary strategy, Prime Therapeutics, a Minnesota-based pharmacy benefit manager.